基本信息
views: 116
![](https://originalfileserver.aminer.cn/sys/aminer/icon/show-trajectory.png)
Bio
Research Interest:
Nanomedicine Research Group :
Our research efforts are directed towards gaining an understanding of membrane structure and function at the molecular level and using the information gained to therapeutic advantage. Particular interests concern investigations on the functional roles of lipids in membranes employing model membrane systems and the generation and use of appropriately engineered liposomal nanoparticulate (LN) systems to deliver conventional and genetic drugs. Our interests in LN systems can be divided into three parts:
LN Delivery of siRNA :
RNA interference is a very attractive strategy for the treatment of human disease; however the therapeutic applicability of siRNAs has been hampered by the ineffective intracellular delivery of functional siRNAs to target cells in vivo. A focus of our laboratory is the design of LN systems that are able to effectively deliver their contents intracellularly following systemic administration, thus enabling the therapeutic use of siRNA. One important aspect of this work is the design and characterization of novel cationic lipids. The challenge in this work is to develop LN systems that are stable when in the circulation but are able to destabilize biological membranes following arrival at target tissue.
LN Delivery of Immunostimulatory Drugs :
In addition to passively accumulating at sites of inflammation and malignant disease, LN delivery systems are naturally taken up by cells of the immune system following systemic administration. For this reason, our research focuses on using LN to enhance the delivery of immunostimulatory oligodeoxynucleotides containing CpG motifs to antigen presenting cells. This work is aimed at stimulating the innate immune system to improve the potency of monoclonal antibodies in cancer therapy as well as developing more effective vaccine adjuvants for use against infectious and malignant disease.
LN Encapsulation of Conventional Chemotherapeutics :
The aim of our research with respect to the encapsulation of conventional chemotherapeutics is to take advantage of the natural tendency of long-circulating LN systems to accumulate at tumour sites. Our research in this area focuses on designing LN delivery systems which have optimized circulation lifetimes, to allow for an increased concentration of drug at the tumour site, and optimized drug release characteristics, to maximize the benefits of providing local sustained release of cell cycle-specific drugs at the site of disease. In addition, we are investigating ways in which to extend the LN technology to drugs that currently are not amenable to loading and retention in LN systems in attempt to increase the therapeutic index of already established drugs. A liposomal formulation of doxorubicin (the most commonly employed anticancer drug) developed in this laboratory is currently in advanced clinical trials in the United States.
Nanomedicine Research Group :
Our research efforts are directed towards gaining an understanding of membrane structure and function at the molecular level and using the information gained to therapeutic advantage. Particular interests concern investigations on the functional roles of lipids in membranes employing model membrane systems and the generation and use of appropriately engineered liposomal nanoparticulate (LN) systems to deliver conventional and genetic drugs. Our interests in LN systems can be divided into three parts:
LN Delivery of siRNA :
RNA interference is a very attractive strategy for the treatment of human disease; however the therapeutic applicability of siRNAs has been hampered by the ineffective intracellular delivery of functional siRNAs to target cells in vivo. A focus of our laboratory is the design of LN systems that are able to effectively deliver their contents intracellularly following systemic administration, thus enabling the therapeutic use of siRNA. One important aspect of this work is the design and characterization of novel cationic lipids. The challenge in this work is to develop LN systems that are stable when in the circulation but are able to destabilize biological membranes following arrival at target tissue.
LN Delivery of Immunostimulatory Drugs :
In addition to passively accumulating at sites of inflammation and malignant disease, LN delivery systems are naturally taken up by cells of the immune system following systemic administration. For this reason, our research focuses on using LN to enhance the delivery of immunostimulatory oligodeoxynucleotides containing CpG motifs to antigen presenting cells. This work is aimed at stimulating the innate immune system to improve the potency of monoclonal antibodies in cancer therapy as well as developing more effective vaccine adjuvants for use against infectious and malignant disease.
LN Encapsulation of Conventional Chemotherapeutics :
The aim of our research with respect to the encapsulation of conventional chemotherapeutics is to take advantage of the natural tendency of long-circulating LN systems to accumulate at tumour sites. Our research in this area focuses on designing LN delivery systems which have optimized circulation lifetimes, to allow for an increased concentration of drug at the tumour site, and optimized drug release characteristics, to maximize the benefits of providing local sustained release of cell cycle-specific drugs at the site of disease. In addition, we are investigating ways in which to extend the LN technology to drugs that currently are not amenable to loading and retention in LN systems in attempt to increase the therapeutic index of already established drugs. A liposomal formulation of doxorubicin (the most commonly employed anticancer drug) developed in this laboratory is currently in advanced clinical trials in the United States.
Research Interests
Papers共 503 篇Author StatisticsCo-AuthorSimilar Experts
By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
BIOSENSORS & BIOELECTRONICS (2024): 116065-116065
Valentina Francia, Yao Zhang,Miffy Hok Yan Cheng,Raymond M. Schiffelers,Dominik Witzigmann,Pieter R. Cullis
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICAno. 11 (2024): e2307803120-e2307803120
Trends in Pharmacological Sciencesno. 5 (2024): 406-418
Mohammad A Anwar, Ammar H Keshteli, Haiyan Yang, Windy Wang, Xukun Li, Helen M Messier,Pieter R Cullis,Christoph H Borchers,Robert Fraser,David S Wishart
Omics : a journal of integrative biologyno. 4 (2024): 182-192
Massimo F. Cau,Francesca Ferraresso, Monica Seadler, Katherine Badior, Youjie Zhang, Laura M. Ketelboeter, Geoffrey Rodriguez, Taylor Chen, Matteo Ferraresso, Amanda Wietrzny,Madelaine Robertson, Amber Haugen,
Molecular Therapy - Methods & Clinical Developmentno. 2 (2024): 101258-101258
Sofie Meulewaeter, Yao Zhang, Abishek Wadhwa, Kevin Fox,Ine Lentacker,Kenneth W. Harder,Pieter R. Cullis,Stefaan C. De Smedt,Miffy H. Y. Cheng,Rein Verbeke
JOURNAL OF MOLECULAR BIOLOGYno. 2 (2024): 168385-168385
Albert Kamanzi, Yao Zhang, Yifei Gu, Faith Liu, Romain Berti, Benjamin Wang,Fariba Saadati,Marco A Ciufolini, Jayesh Kulkarni,Pieter Cullis,Sabrina Leslie
ACS nano (2024)
Amy W. Strilchuk,Woosuk S. Hur,Paul Batty,Yaqiu Sang, Sara R. Abrahams, Alyssa S. M. Yong,Jerry Leung,Lakmali M. Silva,Jocelyn A. Schroeder,Kate Nesbitt,Bas de Laat, Niki M. Moutsopoulos,
SCIENCE TRANSLATIONAL MEDICINEno. 735 (2024): eadh0027-eadh0027
R Verbeke,Pieter R. Cullis
Vaccine Insightsno. 03 (2023): 101-105
Load More
Author Statistics
Co-Author
Co-Institution
D-Core
- 合作者
- 学生
- 导师
Data Disclaimer
The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn